Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors

NCT03425279 is registered in ClinicalTrials.gov with BioAtla, Inc. as lead sponsor.

NCT NCT03425279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03425279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Lead sponsor
BioAtla, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 15, 2018
Completion date
January 8, 2025
Enrollment
245 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

myxofibrosarcoma, undifferentiated pleomorphic sarcoma